GlassScriptPhysician profile
Jonathan L Weyer
NPI 1740442409
$4,004.32
in general payments reported to CMS, 2019-2025
26 companies · $636 in 2025
The $636 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $282 · 2021: $444 · 2022: $850 · 2023: $936 · 2024: $655 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,227.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,216.36 | 2022-2025 | Envista Mx60 Iol, Xiidra, Envista Envy Iol |
| Alcon Vision LLC | $718.63 | 2019-2025 | Hydrus Microstent, Clareon, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $326.17 | 2019-2021 | |
| Allergan, INC. | $201.73 | 2019-2022 | |
| Genentech USA, INC. | $187.39 | 2022-2025 | Vabysmo |
| Carl Zeiss Meditec USA, INC. | $185.20 | 2021-2025 | Cirrus Hd-Oct |
| Biotissue Holdings INC. | $153.46 | 2019-2021 | |
| Abbvie INC. | $122.46 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Mallinckrodt Hospital Products INC. | $121.63 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $91.74 | 2023-2025 | Acuvue |
| Glaukos Corporation | $78.41 | 2022-2025 | Idosetr, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Regeneron Pharmaceuticals, INC. | $75.00 | 2023 | Eylea |
| Ani Pharmaceuticals, INC. | $67.55 | 2024 | Purified Cortrophin Gel |
| New World Medical,INC. | $63.23 | 2022-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Genmab U.S., INC. | $60.39 | 2023 | Tivdak |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $48.16 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $39.82 | 2019-2022 | |
| Ivantis, INC | $39.37 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $34.16 | 2024 | Eylea |
| Thea Pharma INC. | $33.82 | 2023 | |
| Dompe US, INC. | $31.80 | 2024 | Oxervate |
| Rxsight INC | $28.97 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Johnson & Johnson Surgical Vision, INC. | $26.09 | 2024 | Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $23.05 | 2024 | Xdemvy |
| Amgen INC. | $16.34 | 2024 | Tepezza |
| Janssen Pharmaceuticals, INC | $13.39 | 2023 | Acuvue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Weyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.